Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097096 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
A Phase 2 study of Alzheimers Disease, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
- 20
- Study locations
NCT01097096: Completed Phase 2 study of Alzheimers Disease, sponsored by Novartis Pharmaceuticals.
NCT01097096 is a Phase 2 study of Alzheimers Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 177 participants, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01097096, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CAD106
- BIOLOGICAL Alum
- BIOLOGICAL MF59
Study Locations (20)
Other
- Novartis Investigative Site - Antwerp
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Magdeburg
- Novartis Investigative Site - Nuremberg
- Novartis Investigative Site - Amsterdam
Ontario
- Novartis Investigative Site - Toronto
- Novartis Investigative Site - Toronto
Quebec
- Novartis Investigative Site - Greenfield Park
- Novartis Investigative Site - Montreal
RM
- Novartis Investigative Site - Roma
- Novartis Investigative Site - Roma
California
- Novartis Investigative Site - Costa Mesa
Colorado
- Novartis Investigative Site - Boulder
Florida
- Novartis Investigative Site - Hollywood
Indiana
- Novartis Investigative Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01097096 record still lists
NCT01097096 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 3,925-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01097096 names 20 study sites across 13 states, led by Other, Ontario, Quebec.
Frequently Asked Questions
What is clinical trial NCT01097096 about?
NCT01097096 is a clinical study titled "Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients". This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
What is the current status of trial NCT01097096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2010-03. Estimated completion is 2012-12.
What conditions does trial NCT01097096 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01097096?
The interventions under investigation include: Placebo (BIOLOGICAL), CAD106 (BIOLOGICAL), Alum (BIOLOGICAL), MF59 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01097096?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01097096 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01097096's enrollment target sits among peer trials
177 64th of 147 higher than 84 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia